Some participants were not responding to the previous therapies anymore and some participants experienced the return of the cancer. Participants with cancer that was actively growing after their last therapy were not included in the trial. All participants received naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) according to the trial schedule. Society and culture
Legal status
Naxitamab was approved for medical use in the United States in November 2020. References
External links
"Naxitamab". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03363373 for "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow" at ClinicalTrials.gov
Clinical trial number NCT01757626 for "Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma" at ClinicalTrials.gov
Meibomian gland dysfunction (also known as MGD) is a chronic disease of the meibomian glands, which is commonly characterized by obstruction of the end of the duct that delivers the secretion produced by the glands (called meibum) to the eye surface,  which prevents the glandular secretion to reach the ocular surface. The dysfunction could be that the amount of secretion produced may be abnormal (either too little or too much meibum produced). Dysfunction could also be related to the quality of the meibum produced. MGD may result in evaporative dry eye, blepharitis, chalazion, unsealed lid during sleep, and meibomian gland atrophy.MGD causes the glands to be obstructed by thick, cloudy-to-yellow, more opaque and viscous-like, oily and waxy secretions, a change from the glands normal clear secretions. Besides leading to dry eyes, the obstructions can be degraded by bacterial lipases, resulting in the formation of free fatty acids, which irritate the eyes and sometimes cause punctate keratopathy. MGD has been described as "the most underrecognized, underappreciated and undertreated disease in ophthalmic care [...] so common as to be taken as ‘normal’ in many clinical practices".The dysfunction is more often seen in women, and is regarded as the main cause of dry eye syndrome. Factors that contribute to the dysfunction can include things such as a persons age and/or hormones, or severe infestation of Demodex brevis mites. Treatment can include warm compresses to thin the secretions and eyelid scrubs with baby shampoo or eyelid cleanser, or emptying ("expression") of the gland by a professional.